Cargando…
The effect of niacin on serum phosphorus levels in dialysis patients
Hyperphosphatemia is common in patients with end-stage renal disease. Recent studies have shown that niacinamide and niacin achieve clinically significant reductions in serum phosphate in patients undergoing dialysis. The aim of the present study was to evaluate the serum phosphorus lowering effect...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3459519/ https://www.ncbi.nlm.nih.gov/pubmed/23087550 http://dx.doi.org/10.4103/0971-4065.98751 |
_version_ | 1782244811363844096 |
---|---|
author | Edalat-Nejad, M. Zameni, F. Talaiei, A. |
author_facet | Edalat-Nejad, M. Zameni, F. Talaiei, A. |
author_sort | Edalat-Nejad, M. |
collection | PubMed |
description | Hyperphosphatemia is common in patients with end-stage renal disease. Recent studies have shown that niacinamide and niacin achieve clinically significant reductions in serum phosphate in patients undergoing dialysis. The aim of the present study was to evaluate the serum phosphorus lowering effect of niacin in long-term hemodialysis patients. In this 8-week randomized, double-blind clinical trial, 37 patients were assigned to niacin or placebo with titration from 400 to 1000 mg daily. A 2-week washout preceded the switch from niacin to placebo or vice versa. The mean dose of niacin at the end of the 8-week treatment period was 750±200 mg/day. Serum phosphorus decreased from 6.66±1.40 to 5.96±0.87 mg/dL (P = 0.006) in the niacin-treated group after 8-weeks. However, the main reduction occurred at the beginning of study and seems not to be related to the phosphate-lowering effect of drug. In spite of a sharp increase in phosphorus level between w6 and w8 in patients on placebo, phosphorus values in drug-treated group showed nearly steady trend, presumably due to the inhibitory effect of niacin on phosphate absorption from gut. Niacin also increased the high density lipoprotein (HDL) cholesterol (P = 0.018). Our study suggests that niacin should be considered as adjunctive therapy for patients with hyperphosphatemia despite management with phosphate binders. The modest increase in HDL values may be another beneficial effect of this treatment. |
format | Online Article Text |
id | pubmed-3459519 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-34595192012-10-19 The effect of niacin on serum phosphorus levels in dialysis patients Edalat-Nejad, M. Zameni, F. Talaiei, A. Indian J Nephrol Original Article Hyperphosphatemia is common in patients with end-stage renal disease. Recent studies have shown that niacinamide and niacin achieve clinically significant reductions in serum phosphate in patients undergoing dialysis. The aim of the present study was to evaluate the serum phosphorus lowering effect of niacin in long-term hemodialysis patients. In this 8-week randomized, double-blind clinical trial, 37 patients were assigned to niacin or placebo with titration from 400 to 1000 mg daily. A 2-week washout preceded the switch from niacin to placebo or vice versa. The mean dose of niacin at the end of the 8-week treatment period was 750±200 mg/day. Serum phosphorus decreased from 6.66±1.40 to 5.96±0.87 mg/dL (P = 0.006) in the niacin-treated group after 8-weeks. However, the main reduction occurred at the beginning of study and seems not to be related to the phosphate-lowering effect of drug. In spite of a sharp increase in phosphorus level between w6 and w8 in patients on placebo, phosphorus values in drug-treated group showed nearly steady trend, presumably due to the inhibitory effect of niacin on phosphate absorption from gut. Niacin also increased the high density lipoprotein (HDL) cholesterol (P = 0.018). Our study suggests that niacin should be considered as adjunctive therapy for patients with hyperphosphatemia despite management with phosphate binders. The modest increase in HDL values may be another beneficial effect of this treatment. Medknow Publications & Media Pvt Ltd 2012 /pmc/articles/PMC3459519/ /pubmed/23087550 http://dx.doi.org/10.4103/0971-4065.98751 Text en Copyright: © Indian Journal of Nephrology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Edalat-Nejad, M. Zameni, F. Talaiei, A. The effect of niacin on serum phosphorus levels in dialysis patients |
title | The effect of niacin on serum phosphorus levels in dialysis patients |
title_full | The effect of niacin on serum phosphorus levels in dialysis patients |
title_fullStr | The effect of niacin on serum phosphorus levels in dialysis patients |
title_full_unstemmed | The effect of niacin on serum phosphorus levels in dialysis patients |
title_short | The effect of niacin on serum phosphorus levels in dialysis patients |
title_sort | effect of niacin on serum phosphorus levels in dialysis patients |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3459519/ https://www.ncbi.nlm.nih.gov/pubmed/23087550 http://dx.doi.org/10.4103/0971-4065.98751 |
work_keys_str_mv | AT edalatnejadm theeffectofniacinonserumphosphoruslevelsindialysispatients AT zamenif theeffectofniacinonserumphosphoruslevelsindialysispatients AT talaieia theeffectofniacinonserumphosphoruslevelsindialysispatients AT edalatnejadm effectofniacinonserumphosphoruslevelsindialysispatients AT zamenif effectofniacinonserumphosphoruslevelsindialysispatients AT talaieia effectofniacinonserumphosphoruslevelsindialysispatients |